Assessment of Visfatin, GDF-15, and Galectin-3 as a cardio-vascular Risk Stratification Markers among Women with Polycystic Ovary Syndrome
Medical Science Journal for Advance Research · 12.06.2026 · 7 (2)
DOI: 10.46966/msjar.v7i2.408 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Science Journal for Advance Research, online erschienen am 12.06.2026. Verfasst von Abdulkareem M. Jewad und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background & Objective: Emerging evidence highlights chronic inflammation as a key mechanism underlying cardiovascular risk in Polycystic Ovary Syndrome. The objective of this study was to evaluate the inflammatory, metabolic, and cardiovascular-related biomarkers, including visfatin, GDF-15, and galectin-3 in female participants with PCOS and compare them to healthy ones. Materials and methods: A case-control study comprised of 65 women with PCOS and 65 subjects without PCOS (controls). The participants were aged between 20 and 40 years. Serum concentrations of visfatin, GDF-15, and galectin-3 were analyzed via the ELISA technique. Statistical analysis included comparison of clinical and metabolic indicators (BMI, lipid panel, and insulin resistance) between groups. Receiver operating characteristic (ROC) curve analysis was applied to identify the predictive ability of the investigated markers.
Results
Serum amounts of visfatin, GDF-15, and galectin-3 were markedly raised in females with PCOS relative to healthy ones (643.67 ± 210.12 vs. 401.87 ± 69.09, 26.64 ± 9.92 vs. 10.43 ± 3.09, and 151.70 ± 55.26 vs. 101.42 ± 13.18, respectively; all p < 0.001). In addition, PCOS patients demonstrated greater BMI, IR, TC, TG, LDL, and VLDL levels, with notably lower HDL levels compared with controls. ROC curve analysis demonstrated good diagnostic and predictive performance of visfatin, GDF-15, and galectin-3 with AUC values ranging from 0.909 to 0.972.
Conclusion
The findings suggest that visfatin, GDF-15, and galectin-3 may serve as promising inflammatory biomarkers linked with raised cardiovascular risk in patients with this syndrome.
Zitieren
APA
Jewad, A. M., & Abdulnabi, F. A. (2026). Assessment of Visfatin, GDF-15, and Galectin-3 as a cardio-vascular Risk Stratification Markers among Women with Polycystic Ovary Syndrome. Medical Science Journal for Advance Research, 7(2). https://doi.org/10.46966/msjar.v7i2.408
Vancouver
Jewad AM, Abdulnabi FA. Assessment of Visfatin, GDF-15, and Galectin-3 as a cardio-vascular Risk Stratification Markers among Women with Polycystic Ovary Syndrome. Medical Science Journal for Advance Research. 2026;7(2). doi:10.46966/msjar.v7i2.408
BibTeX
@article{Jewad2026,
author = {Jewad, Abdulkareem M. and Abdulnabi, Fadia A.},
title = {Assessment of Visfatin, GDF-15, and Galectin-3 as a cardio-vascular Risk Stratification Markers among Women with Polycystic Ovary Syndrome},
journal = {Medical Science Journal for Advance Research},
year = {2026},
volume = {7},
number = {2},
doi = {10.46966/msjar.v7i2.408}
}
EUVIMED